Description
What it is
The only GHRH analog — originally developed for HIV-associated visceral adiposity research and sold pharmaceutically as Egrifta.
Why it’s studied
Tesamorelin stimulates the pituitary to release growth hormone in natural pulses, elevating IGF-1 selectively. Its FDA-approval pathway makes it one of the best-documented GHRH analogs in research.
Key research findings
-
15-18% reduction in visceral adipose tissue at 26 weeks (Falutz et al., Phase 3 trials)
-
Significant IGF-1 elevation without affecting subcutaneous fat
-
No documented impact on insulin sensitivity in published clinical data
